Investorideas.com

Get investor ideas from our AI, cannabis, cleantech, crypto, gaming, mining, sports podcasts - be a guest or sponsor: call 800 665 0411

 


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology, telemedicine, Covid-19

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech stocks - Feature Your Company & Product Here

Biotech News

Medical Device Firm Engages Distributor for Its TransDermal Infusion System
December 7, 2021 (Investorideas.com Newswire) Sensus Healthcare's "needle-free treatment presents a clear competitive advantage in the aesthetic dermatology space,"

Phase Two Studies Start For Therapy For Chemo-Treated Breast Cancer Patients
December 7, 2021 (Investorideas.com Newswire) New clinical trials for G1 Therapeutics' Cosela are "central to our investment thesis," H.C. Wainright & Co. noted in a new research report.

Biopharma Launches Clinical Trial of Primary Asset in Endometrial Cancer
December 7, 2021 (Investorideas.com Newswire) "Solid tumors offers a substantial opportunity for Karyopharm Therapeutics' Xpovio (selinexor) that perhaps investors have not yet realized,"

Biopharma Launches COVID Vaccine Program in South Africa & Mexico
December 1, 2021 (Investorideas.com Newswire) Oramed Pharmaceuticals' oral vaccine offers "convenience and safety advantages as well as coverage of emergent variant strains

Emerging SARS-COv-2 Variant Is Revenue Growth Opportunity for Vaccine Developer
December 1, 2021 (Investorideas.com Newswire) Just a few days after the WHO deemed the COVID-19 Omicron variant a serious global health concern, leading mRNA-based vaccine developers BioNTech and Pfizer, along with rival Moderna, advised that if needed, the companies would be capable of developing a vaccine for the new mutating strains

Gene Therapy Firm's Shares Rise 120% on Topline Data from Pivotal Dystrophic EB Study
November 30, 2021 (Investorideas.com Newswire) Shares of Krystal Biotech Inc. reached a new 52-week high after the company reported it met both primary and secondary endpoints in its pivotal GEM-3 trial of VYJUVEK

NRx Pharma's COVID-19 Vaccine Displays Effectiveness Against Delta Variant in Phase 2 Clinical Trial
November 30, 2021 (Investorideas.com Newswire) Shares of NRx Pharmaceuticals Inc. traded 50% higher after the company commented on new data released by the Israel Institute for Biological Research regarding the effectiveness of its BriLife COVID-19 Vaccine against the SARS-CoV-2 "Delta" variant.

Biotech Stock News - Marvel Biosciences (TSXV: MRVL) Lead Asset MB-204 Show 47% Reduction in Liver Fibrosis and Active Indications in Multiple Pre-Clinical Models of Nash
Calgary, Alberta - November 23, 2021 (Newsfile Corp.) (Investorideas.com Newswire) Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today announced that it has found its lead asset, MB-204 was active in two different pre-clinical models of non-alcoholic steatohepatitis

Cellular Therapy Co. Earns Rare Pediatric Disease Designation for Infant Congenital Heart Treatment
November 22, 2021 (Investorideas.com Newswire) Shares of Longeveron Inc. traded 50% higher after the company reported that the U.S. FDA approved its Lomecel-B for Rare Pediatric Disease Designation to treat a rare and life-threatening defect in infants called Hypoplastic Left Heart Syndrome.

New Stocks to Watch in Life Sciences (Nasdaq: SERA) (Nasdaq: IINN) (Nasdaq: PRCT) (Nasdaq: SGHT) and Mining (CSE: MUZU)
Point Roberts, WA and Delta, BC - November 19, 2021 (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Life Sciences and Mining.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Related Guest Posts

Buy a guest post on Investorideas.com

Biotech News from Newsfile

Telo Genomics Announces OTCQB Venture Market Listing
Toronto, Ontario--(Newsfile Corp. - December 7, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce its successful uplisting from the OTC Pink Sheets to the OTCQB® Venture Market (the "OTCQB"). TELO commenced trading on the OTCQB at market open on December 06, 2021 under the symbol "TDSGF". TELO common shares will continue to trade on the Toronto Venture Exchange under the symbol TELO.The OTCQB Venture Market, operated...

Relay Changes Its Name to Scryb Inc.
Toronto, Ontario--(Newsfile Corp. - December 7, 2021) - Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) ("Relay" or the "Company") announces that it has filed articles of amendment, with an effective date of December 8, 2021, to change its name to "Scryb Inc." The Company's new stock symbol on the Canadian Securities Exchange will be "SCYB," and the Company expects its shares will commence trading under the new name and ticker symbol on or...

CVR Medical Corp. Announces Additional Patent Grants
Vancouver, British Columbia--(Newsfile Corp. - December 7, 2021) - CVR Medical Corp. (TSXV: CVM) (OTCQB: CRRVF) ("CVR Medical" or the "Company" or "we") a Canadian listed and US based healthcare company in the medical device market is pleased to announce the intention to grant a patent.CVR Medical is pleased to report that the European Patent Office (the "EPO") has issued a Notice of the Intention to Grant application no. 16812333.9 for Non-Invasive Method for Measuring...

Halberd Follow-Up Verification Tests Prove 100% Eradication of TNF-alpha, a Major Contributing Factor to Alzheimer's Disease and PTSD/CTE
Jackson Center, Pennsylvania--(Newsfile Corp. - December 6, 2021) - Halberd Corporation (OTC PINK: HALB) completed verification tests on elimination of Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic cerebral spinal fluid (CSF). These tests confirmed virtually 100% elimination of TNF-alpha through Halberd's patented extracorporeal process, in combination with its patent-pending exposure to tuned laser irradiation. TNF-alpha is an inflammatory cytokine which has been identified as a major contributor to Alzheimer's Disease, and recently has been linked...

Satellos Bioscience Announces New Board Appointments
Satellos welcomes new board members to strengthen its pharmaceutical and North American capital markets expertise in support of its value-build strategyToronto, Ontario--(Newsfile Corp. - December 6, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today the appointment of Dr. Rima Al-awar, PhD and Mr. Adam Mostafa to its board of directors on December 5,...

Subscribe to Biotech News